Who makes BPM31510 Oral Nanosuspension 4%?

BPM31510 Oral Nanosuspension 4% is developed by BPGbio.

What development phase is BPM31510 Oral Nanosuspension 4% in?

BPM31510 Oral Nanosuspension 4% is in Phase 1.

Last reviewed 2026-04-19 · How we verify

BPM31510 Oral Nanosuspension 4%

BPGbio · Phase 1 active Small molecule

At a glance

Generic name	BPM31510 Oral Nanosuspension 4%
Also known as	Coenzyme Q10, CoQ10, ubidecarenone, Coenzyme Q10, CoQ10, ubidecarenone
Sponsor	BPGbio
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Safety Study of Orally Administered BPM31510 in Healthy Subjects (PHASE1)
A Safety Study of Orally Administered BPM31510 in Healthy Subjects (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

BPM31510 Oral Nanosuspension 4% CI brief — competitive landscape report
BPM31510 Oral Nanosuspension 4% updates RSS · CI watch RSS
BPGbio portfolio CI